Navigation Links
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
Date:6/5/2008

dications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its program for MPS IVA, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials related to the enzyme replacement therapy for MPS IVA; the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory agencies, particularly with respect to the enzyme replacement therapy for MPS IVA, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10- K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzy
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Host Research and Development Day June 5th
2. BioMarin to Present at the Bank of America Healthcare Conference
3. BioMarin Announces First Quarter 2008 Financial Results
4. BioMarin to Present at the Morgan Stanley Healthcare Conference
5. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
6. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
9. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
10. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
11. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... Review - 2014 Summary Global Markets ... Review - 2014, provides an overview of the ... focus. This report provides comprehensive information on ... Biotechnology, LLC,s, complete with comparative analysis at various ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... September 30, 2014 Genedata, ... for drug discovery and related life science ... has chosen Genedata Selector as its host-pathogen ... data. FUNGITECT is a European consortium dedicated ... diseases via individualized anti-fungal drug therapies. Genedata ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... The Foundation of UMDNJ, an affiliate of New Jersey ... through the Bill & Melinda Gates Foundation,s Grand Challenges ... overcome persistent bottlenecks in creating new tools that can ... With the grant, Dr. David Alland, professor of ...
... ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused ... and protein products for the industrial enzyme, bioenergy, and ... FibreZyme® G5000, a next generation, high performance ... quality and improve the economics of various pulp and ...
... ARBOR, Mich., March 14, 2012 Synthetic Biologics, ... developer of synthetic DNA-based therapeutics and innovative disease-modifying ... enrollment has been completed in a Phase II ... Synthetic Biologics, proprietary oral formulation of estriol (Trimesta™) ...
Cached Biology Technology:Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 2Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 3Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference 2Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference 3Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 2Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 3Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 4
(Date:9/29/2014)... September 29, 2014 -- Plants have a symbiotic ... the pants extract nutrients and defend against invaders ... contaminating fruits and vegetables. Now, scientist have discovered ... of seeds; thus ensuring that sprouting plants are ... University of Notre Dame, presented their findings today ...
(Date:9/29/2014)... school? According to a new Food and Brand Lab ... can increase participation in the National School Lunch Program ... vegetables by 16%! , Chefs Move to Schools (CMTS), ... chefs with schools in order to provide nutrition instruction ... service workers. , A CMTS event was held in ...
(Date:9/29/2014)... to support the world,s needs to make cheaper ... new and more efficient catalytic materials and processes ... several from Wayne State University, is tackling this ... from the National Science Foundation. , The nearly ... Materials for Electrocatalytic Cascade Reactions," was to Eranda ...
Breaking Biology News(10 mins):Plants prepackage beneficial microbes in their seeds 2Chefs move to schools can increase school meal participation and vegetable intake among students 2Wayne State research aims to develop new, more efficient catalytic materials 2
... news release is available in German . ... remembering painful lessons in German or Latin grammar in school. Languages ... correctly makes the difference between something which "sounds good", and something ... have shown that sensitivity to very simple structural and melodic patterns ...
... list that was established by the EU Scientific ... European young investigators network for Usher syndrome (EUR-USH) ... University Mainz for funding. Out of 82 submitted ... projects that were chosen after a competitive two-step ...
... they have found ,missing heat, in the climate system, casting ... over the past decade. , Observational data on which ... the planet with Polar regions and parts of Africa ... the University of York, and Robert Way, a cryosphere specialist ...
Cached Biology News:Monkeys 'understand' rules underlying language musicality 2European young investigators network for Usher syndrome awarded E-Rare collab project 2'Missing heat' discovery prompts new estimate of global warming 2
... Pipette Tracker is an automated solution for ... and performance testing for all pipettes and ... from any balance Supports all ... 8655, DIN 12650, ISO 9000, NCCLS and ...
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
... Activins are polypeptide hormones which belong ... superfamily. The TGF- superfamily is a ... which control many aspects of development, ... Other members incude TGF-s, bone morphogenetic ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
Biology Products: